Alkermes initiates Phase 2 study evaluating ALKS 2680 in idopathic hypersomnia

Alkermes (ALKS) announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic hypersomnia, or IH. ALKS 2680 is the company’s novel, investigational, oral, selective orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and IH – chronic, neurological disorders characterized by excessive daytime sleepiness. The primary endpoint will assess, by dose level, whether participants taking ALKS 2680 experience a greater decrease in sleepiness compared to participants taking placebo alone. Secondary endpoints include change in Idiopathic Hypersomnia Severity Scale score and incidence of adverse events.